The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of polycystic ovary syndrome, the most common hormone disorder in women of reproductive age and a leading cause of infertility.
The CPG, entitled "Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline" will appear in the December 2013 issue of the Journal of Clinical Endocrinology and Metabolism (JCEM), a publication of The Endocrine Society.
Polycystic ovary syndrome, or PCOS, affects about 5 million women in the United States, according to the National Institutes of Health. The condition causes diverse symptoms, and its causes are poorly understood. The definition and even the name of PCOS have been subject to debate. An NIH panel concluded in January 2013 that the name's focus on a specific symptom - ovarian cysts - that is not present in all PCOS cases caused confusion about the condition. Three separate diagnostic classification systems have been developed to help identify PCOS.
"The Endocrine Society's CPG is designed to help physicians and patients navigate our evolving understanding of this complex condition," said Richard S. Legro, MD, of the Penn State University College of Medicine, and chair of the task force that authored the guideline. "The Society's recommendations allow physicians to make the diagnosis if clear symptoms are present without resorting to universal hormone tests or ultrasound screening."
In the CPG, The Endocrine Society recommends that a diagnosis be made if adult women have two of the three cardinal features of PCOS (diagnostic criteria supported by the NIH panel):
• Excess production of male hormones called androgens.
• Anovulation, a condition where the ovary does not release a mature egg each month. This causes irregular menstrual cycles.
• The formation of clusters of pearl-size cysts containing immature eggs in the ovaries, which is called polycystic ovaries.
Other recommendations from the CPG include: